A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä

Plasma Lipid Metabolites, Clinical Glycemic Predictors, and Incident Type 2 Diabetes




TekijätBegzati, Arjana; Godinez-Macias, Karla P.; Long, Tao; Watrous, Jeramie D.; Moranchel, Rafael; Kantz, Edward D.; Tuomilehto, Jaakko; Havulinna, Aki S.; Niiranen, Teemu J.; Jousilahti, Pekka; Salomaa, Veikko; Yu, Bing; Norby, Faye; Rebholz, Casey M.; Selvin, Elizabeth; Winzeler, Elizabeth A.; Cheng, Susan; Alotaibi, Mona; Goyal, Ravi; Ideker, Trey; Jain, Mohit; Majithia, Amit R.

KustantajaAmerican Diabetes Association

Julkaisuvuosi2025

JournalDiabetes Care

Tietokannassa oleva lehden nimiDiabetes Care

Lehden akronyymiDiabetes Care

Vuosikerta48

Numero3

Aloitussivu473

Lopetussivu480

ISSN0149-5992

eISSN1935-5548

DOIhttps://doi.org/10.2337/dc24-2266

Verkko-osoitehttps://doi.org/10.2337/dc24-2266


Tiivistelmä

OBJECTIVE

Plasma metabolite profiling has uncovered several nonglycemic markers of incident type 2 diabetes (T2D). We investigated whether such biomarkers provide information about specific aspects of T2D etiology, such as impaired fasting glucose and impaired glucose tolerance, and whether their association with T2D risk varies by race.

RESEARCH DESIGN AND METHODS

Untargeted plasma metabolite profiling was performed of participants in the FINRISK 2002 cohort (n = 7,564). Cox regression modeling was conducted to identify metabolites associated with incident T2D during 14 years of follow-up. Metabolites were clustered into pathways using Gaussian graphical modeling. Clusters enriched for T2D biomarkers were further examined for covariation with fasting plasma glucose (FPG), 2-h postchallenge plasma glucose (2hPG), HbA1c, or fasting insulin. Validation analyses and tests of interaction with race were performed in the Atherosclerosis Risk in Communities study.

RESULTS

Two clusters of metabolites, representing diacylglycerols (DAGs) and phosphatidylcholines (PCs), contained the largest number of metabolite associations with incident T2D. DAGs associated with increased T2D incidence (hazard ratio [HR] 1.22; 95% CI 1.14-1.30) independent of FPG, HbA1c, and fasting insulin, but not 2hPG. PCs were inversely associated with T2D risk (HR 0.78; 95% CI 0.71-0.85) independent of FPG, 2hPG, HbA1c, and fasting insulin. No significant interaction between DAGs or PCs and race was observed.

CONCLUSIONS

Fasting DAGs may capture information regarding T2D risk similar to that represented by 2hPG; PCs may capture aspects of T2D etiology that differ from those represented by conventional biomarkers. The direction of effect and strength of DAG and PC associations with incident T2D are similar across European and African Americans.


Julkaisussa olevat rahoitustiedot
This work was supported by grants from the National Institute of Diabetes and Digestive and Kidney Diseases (5R01DK129840) to A.R.M. The Atherosclerosis Risk in Communities study has been funded in whole or in part with federal funds from the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services (contracts 75N92022D00001, 75N92022D00002, 75N92022D00003, 75N92022D00004, and 75N92022D00005). T.J.N. was supported by the Sigrid Jusélius Foundation, the Finnish Foundation for Cardiovascular Research, and the Finnish Research Council (grants 321351 and 354447). V.S. was supported by the Juho Vainio Foundation.


Last updated on 2025-05-03 at 11:03